Nabil specialises in IP and regulatory advice for clients ranging from start-ups to global players, with a particular focus on the life sciences and other technology-rich sectors.

Nabil provides pragmatic, commercially-minded advice with a focus on intellectual property strategy and regulatory compliance. In addition to advice on the identification, protection, commercialisation and enforcement of IP rights, Nabil supports clients with commercial contracts, due diligence, and regulatory compliance.

Prior to training as a solicitor, Nabil worked in early phase pharmaceutical R&D for AstraZeneca and chaired the Physical Organic Chemistry Group of the Royal Society of Chemistry.

显示完整简历 隐藏完整简历

最新新闻和观点

酒店与休闲

Advising IP Group on option exercise to accelerate development of first-in-class gene therapy for patients with cystic fibrosis

2021年10月29日

作者 Colin McCall 以及 Nabil Asaad, PhD

点击此处了解更多
酒店与休闲

Last call before IVDR

Available in Polish

2022年5月17日
Quick read

作者 Bartosz Świdrak

点击此处了解更多
专利与创新

The “unitary effect” of the “European Patent with Unitary Effect”

2022年5月13日
点击此处了解更多
酒店与休闲

New Polish Act on medical devices - Part Three

Available in Polish

2022年5月10日
Briefing

作者 Bartosz Świdrak

点击此处了解更多

与我会面: